G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
Stopped early · Not applicable
Conditions studied: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Sarcoma
In brief
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving colony-stimulating factors, such as G-CSF, to the donor helps the stem cells move from the bone marrow to the blood so they can be collected and stored. PURPOSE: This clinical trial is studying how well a G-CSF-treated donor bone marrow transplant works in treating patients with hematologic cancer or noncancer.
Key facts
- Study ID
- NCT00253552
- Run by
- OHSU Knight Cancer Institute
- People needed
- 4
- Starts
- 2004-05-01
- Expected to finish
- 2006-05-01
- Last updated by the study team
- 2012-05-28
Who can join
Age: any, up to 24. Sex: any. Healthy volunteers: not accepted.
Where it is running
- OHSU Knight Cancer Institute — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.